• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

physIQ Announces eVO2Max Results


Novel approach to estimating maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology presented at an invited oral abstract at the 2022 American Heart Association Scientific Sessions.

The development and validation of PhysIQ's novel digital biomarker to estimate maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology was recently presented in an invited oral abstract during the 2022 American Heart Association’s Scientific Sessions.

eVO2Max can be generated using 24 hours of continuous vital signs and activity data captured during routine daily activities. This enables remote assessment at higher frequency and convenience than by in-clinic tests of cardiopulmonary functional capacity, including cardiopulmonary exercise test (CPET), and the surrogate six-minute walk test (6MWT).

Unlike CPET and 6MWT, which typically require in-clinic visits and extensive patient activity in a sophisticated clinical environment, physIQ’s eVO2Max is performed in the patient’s routine, real-world home environment and requires no special activity protocol. The patient simply wears a small biosensor for several days and physIQ uses the wirelessly transmitted data to derive a daily VO2Max estimate for clinician remote monitoring.

This capability can also provide insight during pharmaceutical clinical trials into the effectiveness of therapies targeting preservation or enhancement of cardiopulmonary function and quality of life for patients. In medical practice, it also has the potential to innovate remote monitoring and care of patients with chronic cardiopulmonary disease, by providing visibility into patient status and identifying early signs of decompensation.

More detailed results on eVO2Max are included in the full press release.

Related Content
© 2024 MJH Life Sciences

All rights reserved.